Compare JAZZ & CSL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | JAZZ | CSL |
|---|---|---|
| Founded | 2003 | 1917 |
| Country | Ireland | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Specialty Chemicals |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.0B | 14.0B |
| IPO Year | 2007 | 1994 |
| Metric | JAZZ | CSL |
|---|---|---|
| Price | $236.27 | $341.73 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 14 | 6 |
| Target Price | $217.57 | ★ $401.67 |
| AVG Volume (30 Days) | ★ 810.7K | 313.6K |
| Earning Date | 05-05-2026 | 04-23-2026 |
| Dividend Yield | N/A | ★ 1.27% |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 4.43 | 3.10 |
| Revenue | $1,618,693,000.00 | ★ $5,003,600,000.00 |
| Revenue This Year | $6.22 | $2.59 |
| Revenue Next Year | $7.68 | $4.50 |
| P/E Ratio | ★ $53.20 | $110.11 |
| Revenue Growth | N/A | ★ 9.08 |
| 52 Week Low | $105.00 | $293.43 |
| 52 Week High | $243.32 | $435.92 |
| Indicator | JAZZ | CSL |
|---|---|---|
| Relative Strength Index (RSI) | 58.56 | 49.18 |
| Support Level | $224.23 | $339.39 |
| Resistance Level | $243.32 | $344.68 |
| Average True Range (ATR) | 6.98 | 9.82 |
| MACD | -1.65 | 0.17 |
| Stochastic Oscillator | 60.69 | 60.48 |
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
Carlisle Companies Inc is a holding company that manufactures and sells single-ply roofing products and warranted systems and accessories for the commercial building industry. It operates through two segments: Carlisle Construction Materials and Carlisle Weatherproofing Technologies. The majority of revenue comes from Carlisle Construction Materials, and more than half of total revenue is earned in the United States. Carlisle Construction Materials produces premium single-ply roofing products and warranted roof systems, including EPDM, TPO, PVC membrane, and polyiso insulation. Carlisle Weatherproofing Technologies produces building envelope solutions, including waterproofing, moisture protection products, air/vapor barriers, and spray polyurethane foam systems.